Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $41.25 Average PT from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has been assigned a consensus rating of “Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $41.25.

A number of research analysts have recently issued reports on ORKA shares. Lifesci Capital started coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective for the company. Leerink Partnrs upgraded shares of Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday. Leerink Partners started coverage on shares of Oruka Therapeutics in a report on Tuesday. They set an “outperform” rating and a $44.00 price objective for the company. Wedbush initiated coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, TD Cowen initiated coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set a “buy” rating on the stock.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $25.00 on Wednesday. Oruka Therapeutics has a 12 month low of $18.72 and a 12 month high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.